7.0T Magnetic Resonance Imaging Study for Hepatic Encephalopathy

April 4, 2025 updated by: Xin Lou, Chinese PLA General Hospital
This clinical trial study aims to detect the imaging characteristics of patients with hepatic encephalopathy (HE) using 7-Tesla (7T) magnetic resonance imaging (MRI).

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

In this study, we analyzed the imaging characteristics of HE. First, with the advantages of 7TMRI, we analyzed the differences in imaging characteristics between HE patients and the healthy, including brain functional imaging and structural imaging. Second, we analyzed the differences in imaging characteristics between different subgroups of HE patients. Finally, we analyzed the correlation between the prognostic results of HE patients after follow-up and the imaging characteristics.

Study Type

Observational

Enrollment (Estimated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Beijing
      • Beijing, Beijing, China, 100853
        • Chinese PLA General Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Patients with hepatic encephalopathy

Description

Inclusion Criteria:

  • Patients with clinical suspected or diagnosed hepatic encephalopathy according to relevant guidelines.The patient's education level is above primary school level.
  • Regular follow-up.

Exclusion Criteria:

  • Contraindications to MRI.
  • Patients with cerebrovascular disease, brain tumors, epilepsy, other neurodegenerative disease.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
7.0T Research
With the advantages of 7.0TMRI, we detect the imaging characteristics of patients with hepatic encephalopathy (HE).
Other: 7.0T MRI-Scan
7.0T MRI-Scan

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Functional connectivity and structural alterations between individuals with different subtypes of HE and healthy subjects.
Time Frame: 5 years
Functional connectivity calculation is mainly based on the BOLD sequence, which is used to describe the degree of connectivity between different brain regions and reflect the functional activity of the brain. Gray matter (GM) morphological destruction, cortical thickness, and subcortical nuclear volume in patients with hepatic encephalopathy were analyzed based on structural magnetic resonance imaging（sMRI）.
5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation between spectral features of clinical variables and spectral features of imaging.
Time Frame: 5 years
The clinical variable spectrum characteristics were constructed using the patients' medical records and test data. The distribution characteristics of clinical psychological characteristics and imaging spectrum characteristics were compared using a multidimensional matrix, and gene-imaging association analysis was used to evaluate imaging changes.
5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chinese PLA General Hospital

Investigators

  • Study Chair: Xin Lou, Chinese PLA General Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 3, 2025

Primary Completion (Estimated)

December 24, 2029

Study Completion (Estimated)

December 24, 2030

Study Registration Dates

First Submitted

April 4, 2025

First Submitted That Met QC Criteria

April 4, 2025

First Posted (Actual)

April 11, 2025

Study Record Updates

Last Update Posted (Actual)

April 11, 2025

Last Update Submitted That Met QC Criteria

April 4, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Hepatic encephalopathy-301

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on MRI

Clinical Trials on 7.0T MRI-Scan

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe